What’s Happening

Collegium Pharmaceutical’s acquisition of AZSTARYS from Corium Therapeutics marks a notable shift in the ADHD market. The $650 million all-cash deal is expected to expand Collegium’s CNS footprint and provide new treatment options for patients.